American Infertility of New York, P.C. v. Deep Blue Health New Zealand Ltd.

CourtDistrict Court, S.D. New York
DecidedJuly 23, 2020
Docket1:17-cv-05666
StatusUnknown

This text of American Infertility of New York, P.C. v. Deep Blue Health New Zealand Ltd. (American Infertility of New York, P.C. v. Deep Blue Health New Zealand Ltd.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
American Infertility of New York, P.C. v. Deep Blue Health New Zealand Ltd., (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

AMERICAN INFERTILITY OF NEW YORK, P.C., ORDER Plaintiff, 17 Civ. 5666 (PGG) (BCM) - against -

DEEP BLUE HEALTH NEW ZEALAND LTD.,

Defendant.

PAUL G. GARDEPHE, U.S.D.J.: Plaintiff American Infertility of New York, P.C. brings this patent infringement action against Defendant Deep Blue Health New Zealand Ltd. (Cmplt. (Dkt. No. 1)) This Court entered an Order of Default against Defendant (Dkt. No. 52) and referred this case to Magistrate Judge Barbara Moses for an inquest on damages. (Dkt. No. 51) Judge Moses issued a Report and Recommendation (“R&R”) in which she recommends that Plaintiff be awarded $1.00 in nominal damages and $4,272.60 in costs. (R&R (Dkt. No. 59) at 22) Judge Moses also recommends that Defendant be permanently enjoined from infringing on U.S. Patent No. 8,067,400 (the “‘400 Patent”). (Id.) For the reasons stated below, the R&R will be adopted in its entirety. BACKGROUND I. FACTS1 On November 29, 2011, the U.S. Patent and Trademark Office issued the ‘400

1 The parties have not objected to Judge Moses’ recitation of the alleged facts. Accordingly, the Court adopts her account of the facts in full. See Silverman v. 3D Total Solutions, Inc., No. 18 CIV. 10231 (AT), 2020 WL 1285049 (S.D.N.Y. Mar. 18, 2020) (“Because the parties have not Patent, titled “Androgen Treatment in Females,” to Plaintiff. (Cmplt. (Dkt. No. 1) ¶ 10) The ‘400 Patent is “generally directed to a method for improving the quality of embryos, increasing pregnancy rates, and reducing miscarriage rates by administrating an androgen.” (Id. ¶ 12) Claim 1 of the ‘400 Patent is a “method of decreasing aneuploidy rates in human embryos

comprising administering androgen to a female for at least two months.” (Id. ¶ 19) Claim 3 is a “method according to claim 1, wherein said androgen is dehydroepiandrosterone [(“DHEA”)].” (Id. ¶ 20) Claim 4 is a “method according to claim 3, wherein . . . [DHEA] administration comprises between 50 and 100 mg per day.” (Id. ¶ 21) Claim 6 is a method of decreasing time to pregnancy and increasing pregnancy rates by administering the androgen for at least two months. (Id. ¶ 22) Plaintiff is a New York professional corporation and the assignee and owner of all rights, title, and interest in and to the ‘400 Patent, including the right to assert causes of action arising under the patent and the right to seek and recover for infringement. (Id. ¶ 13) Defendant is a New Zealand corporation that conducts business in the United States. (Id. ¶ 2)

Plaintiff alleges that Defendant has infringed, and has induced others to infringe, on the ‘400 Patent “by manufacturing, promoting, marketing, making, having made, using, importing, offering for sale, advertising, selling or otherwise making available, within the State of New York and elsewhere throughout the United States, products, including but not limited to DHEA 25mg (the Infringing Product), that contains dehydroepiandrosterone (DHEA) and are administered in accordance with the limitations of at least one claim of the ‘400 patent.” (Id. ¶ 5)

objected to the R&R’s characterization of the background facts . . . , the Court adopts the R&R’s ‘Background’ section. . . .”). Given Defendant’s default, these facts are assumed to be true. Idir v. La Calle TV, LLC, No. 19-CV-6251 (JGK), 2020 WL 4016425, at *2 (S.D.N.Y. July 15, 2020) (“In the event of a defendant’s default, the plaintiff’s properly pleaded allegations in the complaint, except those related to damages, are accepted as true.”). II. PROCEDURAL HISTORY Plaintiff commenced this action on July 26, 2017, asserting a claim of patent infringement in violation of 35 U.S.C § 271(a)-(b). (Id. ¶ 34) Deep Blue Health was served on March 9, 2018. (Proof of Service (Dkt. No. 26)) On June 11, 2018, Judge Katherine Forrest – to

whom this case was then assigned – issued an order noting that her chambers had received a “document via email” which “appear[ed] to be from [D]efendant’s counsel.” (Dkt. No. 28) Judge Forrest refused to accept the document as “properly filed” because Defendant had not appeared in the case. (Id.) On July 16, 2018, at Plaintiff’s request, the Clerk of Court issued a certificate of default against Defendant. (Dkt. No. 41) On August 20, 2018, Plaintiff moved for a default judgement. (Dkt. No. 45) On August 24, 2018, Judge Forrest directed Defendant to show cause – at a hearing scheduled for September 27, 2018 – why a default judgement should not be entered. (Dkt. No. 46) On September 20, 2018, this case was reassigned to this Court. On October 5,

2018, this Court rescheduled the September 27 hearing for October 10, 2018. (Order (Dkt. No. 49); Oct. 10, 2020 Tr. (Dkt. No. 55) at 2) Defendant was served with the October 5, 2018 order (Dkt. No. 50), but did not appear at the October 10, 2018 hearing. (Oct. 10, 2020 Tr. (Dkt. No. 55)) Instead, on October 10, 2018, Defendant submitted “Defendant’s Submissions on the Application of the Law.” (Id. at 4) Because no lawyer had appeared on behalf of Defendant, this Court ruled that the arguments in Defendant’s submission could not be considered. (Id. at 2- 3) The Court noted, however, that Defendant’s submissions left “no question that effective service was made” and that Defendant “was on notice of these proceedings and has chosen not to appear.” (Id. at 4) After the October 10, 2018 hearing, this Court issued an Order of Default against Defendant. (Dkt. No. 52) The same day, the Court referred the case to Judge Moses for an inquest on damages. (Dkt. No. 51) On December 11, 2018, Plaintiff submitted Proposed Findings of Facts and

Conclusions of Law, seeking $10,000.00 in nominal damages, $24,250.00 in attorneys’ fees, $19,250.00 in consulting fees, and $4,272.60 in costs. (Proposed Findings of Facts and Conclusions of Law (Dkt. No. 57) ¶¶ 9, 13) Plaintiff also seeks a permanent injunction enjoining Defendant from infringing on the ‘400 Patent. (Id. ¶ 14) On December 30, 2019, Judge Moses issued a 23-page R&R, in which she recommends granting the requested injunction and awarding $1.00 in nominal damages and $4,272.60 in costs but otherwise denying the requested relief. (R&R (Dkt. No. 59) at 22) The R&R notifies the parties that they have 14 days to file any objections pursuant to 28 U.S.C. § 636(b)(1) and Fed. R. Civ. P. 72(b). (Id. at 23) The R&R further states that the “[f]ailure to file timely objections will result in a waiver of objections and will preclude appellate review.”

(Id. (emphasis omitted)) Neither side has filed objections to the R&R. DISCUSSION I. LEGAL STANDARD In reviewing a report and recommendation, a district court “may accept, reject, or modify, in whole or in part, the findings or recommendations made by the magistrate judge.” 28 U.S.C. § 636(b)(1)(C). Where a timely objection has been made to the magistrate judge’s recommendations, the district court judge “shall make a de novo determination of those portions of the report or specified proposed findings or recommendations to which objection is made.” Id. Where, as here, no objections are filed to a magistrate judge’s R&R – despite clear warning that a failure to file objections will result in a waiver of judicial review – judicial review has been waived. See Thomas v. Arn, 474 U.S. 140, 147-48 (1985); see also Mario v. P & C Food Markets, Inc.,

Related

Black v. Thorne
111 U.S. 122 (Supreme Court, 1884)
Carey v. Piphus
435 U.S. 247 (Supreme Court, 1978)
Thomas v. Arn
474 U.S. 140 (Supreme Court, 1986)
Anthony Romandette v. Weetabix Company, Inc.
807 F.2d 309 (Second Circuit, 1986)
Licci Ex Rel. Licci v. Lebanese Canadian Bank, SAL
673 F.3d 50 (Second Circuit, 2012)
Marc Andrew Mario v. P & C Food Markets, Inc.
313 F.3d 758 (Second Circuit, 2002)
Finkel v. Romanowicz
577 F.3d 79 (Second Circuit, 2009)
Funai Elec. Co., Ltd. v. Daewoo Electronics Corp.
593 F. Supp. 2d 1088 (N.D. California, 2009)
Small v. NOBEL BIOCARE USA, LLC
808 F. Supp. 2d 584 (S.D. New York, 2011)
Trustees of Columbia University v. Roche Diagnostics GmbH
272 F. Supp. 2d 90 (D. Massachusetts, 2002)
American Can Co. v. Goldee Mfg. Co.
31 F.2d 492 (E.D. New York, 1927)
American Can Co. v. Goldee Manufacturing Co.
31 F.2d 494 (Second Circuit, 1929)
Octane Fitness, LLC v. Icon Health
134 S. Ct. 1749 (Supreme Court, 2014)
Ebay Inc. v. Mercexchange, L. L. C.
547 U.S. 388 (Supreme Court, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
American Infertility of New York, P.C. v. Deep Blue Health New Zealand Ltd., Counsel Stack Legal Research, https://law.counselstack.com/opinion/american-infertility-of-new-york-pc-v-deep-blue-health-new-zealand-ltd-nysd-2020.